- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Co-Op Failures Could Have Been Avoided
What we're reading, December 24, 2015: more than half of Affordable Care Act co-ops will be closed by the end of 2015, but this could have been avoided; 5 senators are pressing CMS for information on containing drug costs; and a task force does not recommend screening all teens and children for high cholesterol.
More than half of the co-ops created by the Affordable Care Act will no longer exist by the end of 2015, but this could have been avoided, according to Modern Healthcare. The co-ops struggled with sick, costly patients who were unfamiliar with health insurance and fewer payments from the federal government than initially promised. However, if Congress had paid out what was promised, the co-ops would not have failed, according to insiders.
Five senators are pressing CMS to provide more information on its efforts to contain prescription drug costs and assist seniors. A letter from the 5 Democrats asks how the agency will improve drug pricing transparency and bring down costs, according to a blog post from the Association of Health Care Journalists. The senators sit on committees that oversee issues related to Medicare, Medicaid, and healthcare costs.
The United States Preventive Services Task Force has determined that there is not enough evidence to recommend screening all children and teens for high cholesterol. The draft recommendation remains unchanged from 2007 as it is unclear if screening before the age of 20 reduces the risk of cardiovascular disease later in life, reported HealthDay. The experts added that potential harms for long-term use of cholesterol-lowering medications is still unknown.
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
